Role of CD8-positive Cells in Radioimmunotherapy Utilizing (177)Lu-mAbs in an Immunocompetent Rat Colon Carcinoma Model

Overview

Journal EJNMMI Res

Date 2015 Apr 9

PMID 25853009

Citations 1

Authors

Erika Elgstrom

Sophie E Eriksson

Tomas G Ohlsson

Rune Nilsson

Jan Tennvall

Affiliations

Soon will be listed here.

Abstract

Background: CD8-positive cells might play a crucial role in the therapeutic response to radiation, which has however not been investigated in radioimmunotherapy (RIT). The aim of this study was to evaluate whether cytotoxic T cells affect the response of established tumors and, above all, if they delay or prevent the development of distant metastases after RIT, using an immunocompetent syngeneic rat colon carcinoma model.

Methods: The cytotoxic T cells were depleted in 15 rats by anti-CD8 before the injection of the radioimmunoconjugate (400 MBq/kg body weight (177)Lu-BR96, which binds to the tumor-associated antigen Lewis Y). Fifteen other rats were treated with RIT only. Both groups were followed for 99 days. Blood samples were collected at least once weekly, and tumors were monitored twice weekly.

Results: Twenty-nine of the 30 animals exhibited local complete response. The non-responder was treated with anti-CD8 and RIT but succumbed later due to metastases. Five animals in the group given anti-CD8 + RIT were sacrificed due to metastatic disease, and 4 additional animals were found to have metastases at autopsy. In the group given RIT, 4 animals developed metastatic disease, but no metastases were found in the remaining 11 animals at autopsy. Thus, at the end of the study, 6 animals in the anti-CD8 + RIT group were free from metastases, while 11 were free from metastases in the group receiving RIT. CD3(+)CD4(-)CD8(+) lymphocytes were consistently depleted by the anti-CD8 treatment. The myelosuppression was otherwise similar in the two groups. The initial depletion of CD8-positive cells in our syngeneic rat colon carcinoma model resulted in a higher frequency of animals developing metastases.

Conclusions: Depletion of CD8-positive cells during RIT in an immunocompetent rat tumor model might influence the number of animals developing metastases, indicating that the immune system may be important in the long-term outcome of RIT.

Citing Articles

Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model.

Elgstrom E, Eriksson S, Ljungberg O, Bendahl P, Ohlsson T, Nilsson R EJNMMI Res. 2015; 5(1):47.

PMID: 26374556 PMC: 4571030. DOI: 10.1186/s13550-015-0126-y.

References

Eriksson S, Ohlsson T, Nilsson R, Tennvall J . Treatment with unlabeled mAb BR96 after radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model. Cancer Biother Radiopharm. 2012; 27(3):175-82. DOI: 10.1089/cbr.2011.1132. View

Eriksson S, Ohlsson T, Nilsson R, Tennvall J . Repeated radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model. Cancer Biother Radiopharm. 2012; 27(2):134-40. DOI: 10.1089/cbr.2011.1080. View

Holmdahl R, Olsson T, Moran T, Klareskog L . In vivo treatment of rats with monoclonal anti-T-cell antibodies. Immunohistochemical and functional analysis in normal rats and in experimental allergic neuritis. Scand J Immunol. 1985; 22(2):157-69. DOI: 10.1111/j.1365-3083.1985.tb01868.x. View

Bhandoola A, von Boehmer H, Petrie H, Zuniga-Pflucker J . Commitment and developmental potential of extrathymic and intrathymic T cell precursors: plenty to choose from. Immunity. 2007; 26(6):678-89. DOI: 10.1016/j.immuni.2007.05.009. View

Koch U, Radtke F . Mechanisms of T cell development and transformation. Annu Rev Cell Dev Biol. 2011; 27:539-62. DOI: 10.1146/annurev-cellbio-092910-154008. View

Seung S, Curti B, Crittenden M, Urba W . Radiation and immunotherapy: Renewed allies in the war on cancer. Oncoimmunology. 2012; 1(9):1645-1647. PMC: 3525632. DOI: 10.4161/onci.21746. View

Wee Y, Choi M, Kang C, Kim Y, Kim J, Lee S . The synergistic effect of Tautomycetin on Cyclosporine A-mediated immunosuppression in a rodent islet allograft model. Mol Med. 2010; 16(7-8):298-306. PMC: 2896462. DOI: 10.2119/molmed.2009.00099. View

Frey B, Rubner Y, Kulzer L, Werthmoller N, Weiss E, Fietkau R . Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother. 2013; 63(1):29-36. PMC: 11028436. DOI: 10.1007/s00262-013-1474-y. View

Prudhomme G, Sanders R, Parfrey N . T-cell maturation and clonal deletion in cyclosporine-induced autoimmunity. J Autoimmun. 1991; 4(2):357-68. DOI: 10.1016/0896-8411(91)90030-g. View

10.

Gough M, Crittenden M, Sarff M, Pang P, Seung S, Vetto J . Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother. 2010; 33(8):798-809. PMC: 3563298. DOI: 10.1097/CJI.0b013e3181ee7095. View

11.

Parel Y, Chizzolini C . CD4+ CD8+ double positive (DP) T cells in health and disease. Autoimmun Rev. 2004; 3(3):215-20. DOI: 10.1016/j.autrev.2003.09.001. View

12.

Martensson L, Nilsson R, Ohlsson T, Sjogren H, Strand S, Tennvall J . High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model. Cancer. 2010; 116(4 Suppl):1043-52. DOI: 10.1002/cncr.24791. View

13.

Siva S, MacManus M, Martin R, Martin O . Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. 2013; 356(1):82-90. DOI: 10.1016/j.canlet.2013.09.018. View

14.

Hellstrom I, Garrigues H, Garrigues U, Hellstrom K . Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res. 1990; 50(7):2183-90. View

15.

Sjogren H, Isaksson M, WILLNER D, Hellstrom I, Hellstrom K, Trail P . Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res. 1997; 57(20):4530-6. View

16.

Forrer F, Chen J, Fani M, Powell P, Lohri A, Muller-Brand J . In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. Eur J Nucl Med Mol Imaging. 2009; 36(9):1443-52. DOI: 10.1007/s00259-009-1120-2. View

17.

Elgstrom E, Ljungberg O, Eriksson S, Orbom A, Strand S, Ohlsson T . Change in cell death markers during (177)Lu-mAb radioimmunotherapy-induced rejection of syngeneic rat colon carcinoma. Cancer Biother Radiopharm. 2014; 29(4):143-52. DOI: 10.1089/cbr.2013.1576. View

18.

Beijleveld L, Damoiseaux J, Van Breda Vriesman P . Differential effects of X-irradiation and cyclosporin-A administration on the thymus with respect to the generation of cyclosporin-A-induced autoimmunity. Dev Immunol. 1995; 4(2):127-38. PMC: 2275949. DOI: 10.1155/1995/18495. View

19.

Ortolani C, Forti E, Radin E, Cibin R, Cossarizza A . Cytofluorimetric identification of two populations of double positive (CD4+,CD8+) T lymphocytes in human peripheral blood. Biochem Biophys Res Commun. 1993; 191(2):601-9. DOI: 10.1006/bbrc.1993.1260. View

20.

Wu L . T lineage progenitors: the earliest steps en route to T lymphocytes. Curr Opin Immunol. 2006; 18(2):121-6. DOI: 10.1016/j.coi.2006.01.006. View